blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3670528

EP3670528 - SCLEROSTIN BINDING AGENTS [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  06.08.2021
Database last updated on 07.03.2026
FormerGrant of patent is intended
Status updated on  30.03.2021
FormerExamination is in progress
Status updated on  09.10.2020
FormerRequest for examination was made
Status updated on  24.07.2020
FormerThe application has been published
Status updated on  22.05.2020
Most recent event   Tooltip26.05.2023Opposition procedure terminated - date of legal effect publishedpublished on 28.06.2023  [2023/26]
Applicant(s)For all designated states
UCB Pharma S.A.
Allée de la Recherche 60
1070 Brussels / BE
For all designated states
Amgen, Inc
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 / US
[2020/26]
Inventor(s)01 / PASZTY, Christopher
6310 Canary Str.
Ventura, California 93003 / US
02 / ROBINSON, Martyn Kim
208 Bath Road
Slough, Berkshire SL1 3WE / GB
03 / GRAHAM, Kevin
1627 Charterwood Court
Thousand Oaks, California 91362 / US
04 / HENRY, Alistair James
92 Cowley Road
Uxbridge, Middlesex UB8 2LX / GB
05 / HOFFMAN, Kelly Sue
795 Green Valley Drive
Newbury Park, California 91320 / US
06 / LATHAM, John
2409 10th Avenue West
Seattle, Washington 98119 / US
07 / LAWSON, Alastair
208 Bath Road
Slough, Berkshire SL1 3WE / GB
08 / LU, Hsieng Sen
2758 Rainfield Avenue
Westlake Village, California 91362 / US
09 / POPPLEWELL, Andy
208 Bath Road
Slough, Berkshire SL1 3WE / GB
10 / SHEN, Wenyan
2757 Autumn Ridge Drive
Thousand Oaks, California 91362 / US
11 / WINKLER, David
127 George Street
Arlington, Massachusetts 02476-7326 / US
12 / WINTERS, Aaron George
2501 Pierpont Boulevard
Ventura, California 93001 / US
 [2020/26]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2020/26]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date19211623.428.04.2006
[2020/26]
Priority number, dateUS20050677583P03.05.2005         Original published format: US 677583 P
US20060776847P24.02.2006         Original published format: US 776847 P
US20060782244P13.03.2006         Original published format: US 782244 P
US20060792645P17.04.2006         Original published format: US 792645 P
US2006041100325.04.2006         Original published format: US 411003
[2020/26]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3670528
Date:24.06.2020
Language:EN
[2020/26]
Type: B1 Patent specification 
No.:EP3670528
Date:08.09.2021
Language:EN
[2021/36]
Search report(s)(Supplementary) European search report - dispatched on:EP26.03.2020
ClassificationIPC:C07K14/51, C07K16/18
[2020/26]
CPC:
C07K16/22 (EP,CN,US); C07K16/18 (EA,NO,US); C07K16/28 (KR);
A61K39/395 (EA); A61K39/39533 (NO); A61K39/3955 (NO,US);
A61K45/06 (US); A61K47/60 (EP,US); A61P1/02 (EP);
A61P1/04 (EP); A61P1/16 (EP); A61P15/00 (EP);
A61P15/12 (EP); A61P17/00 (EP); A61P19/00 (EP);
A61P19/02 (EP); A61P19/08 (EP,EA,NO); A61P19/10 (EP,EA,NO);
A61P25/00 (EP); A61P25/08 (EP); A61P25/32 (EP);
A61P29/00 (EP); A61P3/00 (EP); A61P3/02 (EP);
A61P3/04 (EP); A61P3/10 (EP); A61P37/00 (EP);
A61P43/00 (EP); A61P5/14 (EP); A61P5/16 (EP);
A61P5/18 (EP); A61P7/00 (EP); A61P7/06 (EP);
C07K14/51 (EP,EA,NO,US); C07K14/76 (US); C07K14/79 (US);
C07K16/00 (KR); C12N15/63 (EP,US); A61K2039/505 (EP,CN,US);
C07K2317/24 (EP,NO,US); C07K2317/33 (CN); C07K2317/34 (US);
C07K2317/565 (NO,US); C07K2317/76 (EP,NO,US); C07K2317/92 (EP,NO,US);
C07K2319/30 (US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2020/35]
Former [2020/26]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL16.07.2020
BA16.07.2020
HR16.07.2020
MK16.07.2020
YU16.07.2020
TitleGerman:SCLEROSTINBINDENDE WIRKSTOFFE[2020/26]
English:SCLEROSTIN BINDING AGENTS[2020/26]
French:AGENTS DE LIAISON DE LA SCLÉROSTINE[2020/26]
Examination procedure16.07.2020Amendment by applicant (claims and/or description)
16.07.2020Examination requested  [2020/35]
16.07.2020Date on which the examining division has become responsible
08.10.2020Despatch of a communication from the examining division (Time limit: M04)
09.10.2020Reply to a communication from the examining division
31.03.2021Communication of intention to grant the patent
03.08.2021Fee for grant paid
03.08.2021Fee for publishing/printing paid
03.08.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP06751903.3  / EP1891101
EP10014374.2  / EP2325200
Divisional application(s)EP21188463.0  / EP3985015
Opposition(s)Opponent(s)01  07.06.2022  06.02.2023  WITHDRAWN
James Poole Limited
One Southampton Row
London WC1B 5HA / GB
Opponent's representative
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 [2023/11]
Former [2022/28]
Opponent(s)01  07.06.2022  09.06.2022  ADMISSIBLE
James Poole Limited
One Southampton Row
London WC1B 5HA / GB
Opponent's representative
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
23.06.2022Invitation to proprietor to file observations on the notice of opposition
03.11.2022Reply of patent proprietor to notice(s) of opposition
14.02.2023Despatch of communication that the opposition procedure will be closed
24.02.2023Legal effect of closure of opposition procedure [2023/26]
Fees paidRenewal fee
26.11.2019Renewal fee patent year 03
26.11.2019Renewal fee patent year 04
26.11.2019Renewal fee patent year 05
26.11.2019Renewal fee patent year 06
26.11.2019Renewal fee patent year 07
26.11.2019Renewal fee patent year 08
26.11.2019Renewal fee patent year 09
26.11.2019Renewal fee patent year 10
26.11.2019Renewal fee patent year 11
26.11.2019Renewal fee patent year 12
26.11.2019Renewal fee patent year 13
26.11.2019Renewal fee patent year 14
31.03.2020Renewal fee patent year 15
15.04.2021Renewal fee patent year 16
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipIS08.01.2022
[2022/25]
Documents cited:Search[Y] WO2005014650  (CELLTECH R & D INC et al.)
 [Y] WO2005003158  (CELLTECH R & D INC et al.)
 [Y]   WARMINGTON K ET AL: "Scierostin antagonism in adult rodents, via monoclonal antibody mediated blockade, increases bone mineral density and implicates sclerostin as a key regulator of bone mass during adulthood", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 19, October 2004 (2004-10-01), & 26TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-FOR-BONE-AND-MINERAL-RESE ARCH; SEATTLE, WA, USA; OCTOBER 01 -05, 2004, pages S56 - S57, XP009072609, ISSN: 0884-0431

DOI:   http://dx.doi.org/10.1359/JBMR.0301211
 [A]   AVSIAN-KRETCHMER ORNA ET AL: "Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists.", MOLECULAR ENDOCRINOLOGY (BALTIMORE, MD.) JAN 2004, vol. 18, no. 1, January 2004 (2004-01-01), pages 1 - 12, XP002400896, ISSN: 0888-8809
by applicantUS6395511
 US6803453
 US2004009535
 US2005106683
 US6703199
 US2005238646
 US4331647
 US4640835
 US4496689
 US4301144
 US4670417
 US4791192
 US4179337
 US6133426
 USRE32011
 US4902614
 US4543439
 US4411993
 US5877397
 US4464456
 WO9202551
 US5627052
 US5223409
 US5698426
 US2004146888
 US86849707
 US200360478977
 US5543158
 US5641515
 US5399363
 US5466468
 US5567434
 US5552157
 US5565213
 US5738868
 US5795587
 US5145684
   RIGGS, WEST J. MED., vol. 154, 1991, pages 63 - 77
   KHOSLARIGGS, MAYO CLIN. PROC., vol. 70, 1995, pages 978982
   BRUNKOW ET AL., AM. J. HUM. GENET., vol. 68, 2001, pages 577 - 589
   BALEMANS ET AL., HUM. MOL. GENET., vol. 10, 2001, pages 537 - 543
   HOLLINGERHUDSON, NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1126 - 1136
   NISONOFF ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 89, 1960, pages 230
   PORTER, BIOCHEM. J., vol. 73, 1959, pages 119
   EDELMAN: "Methods in Enzymology", vol. 1, 1967, ACADEMIC PRESS, pages: 422
   BOERNER ET AL., J. IMMUNOL., vol. 147, 1991, pages 86 - 95
   LARRICK ET AL., METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, vol. 2, 1991, pages 106
   COURTENAY-LUCK ET AL.: "Monoclonal Antibodies: Production, Engineering and Clinical Application", 1995, CAMBRIDGE UNIVERSITY PRESS, article "Genetic Manipulation of Monoclonal Antibodies", pages: 166
   WARD ET AL.: "Monoclonal Antibodies: Principles and Applications", 1995, WILEY-LISS, INC., article "Genetic Manipulation and Expression of Antibodies", pages: 137
   MOULT J., CURR. OP. IN BIOTECH., vol. 7, no. 4, 1996, pages 422 - 427
   CHOU ET AL., BIOCHEMISTRY, vol. 113, no. 2, 1974, pages 211 - 222
   CHOU ET AL., ADV. ENZYMOL. RELAT. AREAS MOL. BIOL., vol. 47, 1978, pages 45 - 148
   CHOU ET AL., ANN. REV. BIOCHEM., vol. 47, pages 251 - 276
   CHOU ET AL., BIOPHYS. J., vol. 26, 1979, pages 367 - 384
   HOLM ET AL., NUCL. ACID. RES., vol. 27, no. 1, 1999, pages 244 - 247
   BRENNER ET AL., CURR. OP. STRUCT. BIOL., vol. 7, no. 3, 1997, pages 369 - 376
   JONES, D., CURR. OPIN. STRUCT. BIOL., vol. 7, no. 3, 1997, pages 377 - 87
   SIPPL ET AL., STRUCTURE, vol. 4, no. 1, 1996, pages 15 - 19
   BOWIE ET AL., SCIENCE, vol. 253, 1991, pages 164 - 170
   GRIBSKOV ET AL., METH. ENZYM., vol. 183, 1990, pages 146 - 159
   GRIBSKOV ET AL., PROC. NAT. ACAD. SCI., vol. 84, no. 13, 1987, pages 4355 - 4358
   KRAMER ET AL., NUCLEIC ACIDS RES., vol. 12, 1984, pages 9441
   THORNTON ET AL., NATURE, vol. 354, 1991, pages 105
   NYGRENUHLEN, CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 7, 1997, pages 463 - 469
   ZHANG, W. ET AL., MOLECULAR IMMUNOLOGY., vol. 42, no. 12, 2005, pages 1445 - 1451
   DALL'ACQUA WF ET AL., METHODS, vol. 36, no. 1, 2005, pages 3 5 - 60
   CLARK, M., IMMUNOLOGY TODAY, vol. 21, no. 8, 2000, pages 397 - 402
   KUNKEL ET AL., METHODS IN ENZYMOL., vol. 154, 1987, pages 367 - 82
   PLUCKTHUN ET AL., METHODS ENZYMOL., vol. 178, 1989, pages 497 - 515
   GLASKY ET AL., HYBRIDOMA, vol. 8, 1989, pages 377 - 89
   SANGER ET AL., PNAS, vol. 74, 1977, pages 5463
   KUNKEL, PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 - 92
   MOUNTAIN AADAIR, J R: "Intercept", 1992, article "Biotechnology and Genetic Engineering Reviews"
   "Current Protocols in Molecular Biology", 1999, WILEY INTERSCIENCE
   YANG ET AL., J. MOL. BIOL., vol. 254, 1995, pages 392 - 403
   MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783
   THOMPSON ET AL., J. MOL. BIOL., vol. 256, 1996, pages 350 - 368
   BRUGGEMANN ET AL., CURR. OPIN. BIOTECHNOL., vol. 8, 1997, pages 455 - 733
   CRAMERI ET AL., NATURE, vol. 391, 1998, pages 288 - 291
   VAUGHAN ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 535 - 539
   KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
   "Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses", 1980, PLENUM PRESS
   BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
   PICKSLEY ET AL.: "E. coli,'' in DNA Cloning 2: Expression Systems", 1995, OXFORD UNIVERSITY PRESS, article "Production of monoclonal antibodies against proteins expressed", pages: 93
   BAINES ET AL.: "Methods in Molecular Biology", vol. 10, 1992, THE HUMANA PRESS, INC., article "Purification of Immunoglobulin G (IgG", pages: 79 - 104
   GREEN ET AL., NATURE GENET., vol. 7, 1994, pages 13
   LONBERG ET AL., NATURE, vol. 368, 1994, pages 856
   TAYLOR ET AL., INT. IMMUN., vol. 6, 1994, pages 579
   JAKOBOVITS ET AL., ANN. N. Y. ACAD. SCI., vol. 764, 1995, pages 525 - 35
   BRUGGEMANN ET AL., CURRO OPIN. BIOTECHNOL., vol. 8, 1997, pages 455 - 58
   BABCOOK ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 7843 - 48
   WINTER ET AL., ANNU. REV. IMMUNOL., vol. 12, 1994, pages 433 - 55
   BURTON ET AL., ADV. IMMUNOL., vol. 57, 1994, pages 191 - 280
   HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 81
   SASTRY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 5728 - 32
   ALTING-MEES ET AL., STRATEGIES IN MOLECULAR BIOLOGY, vol. 3, 1990, pages 1 - 9
   KANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 4363 - 66
   HOOGENBOOM ET AL., J. MOLEC. BIOL., vol. 227, 1992, pages 381 - 388
   SCHLEBUSCH ET AL., HYBRIDOMA, vol. 16, 1997, pages 47 - 52
   HARRIS, RJ., JOURNAL OF CHROMATOGRAPHY, vol. 705, 1995, pages 129 - 134
   ANGAL S ET AL., MOL IMMUNOL, vol. 30, no. 1, 1993, pages 105 - 108
   KABAT ET AL.: "Sequences of Proteins of Immunological Interest", U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, 1987
   SCATCHARD ET AL., ANN. N.Y. ACAD. SCI., vol. 51, 1949, pages 660 - 672
   WOLFF ET AL., CANCER RES., vol. 53, 1993, pages 2560 - 65
   SUDO HKODAMA H-AAMAGAI YYAMAMOTO SKASAI S: "In vitro differentiation and calcification in a new clonal osteogenic cell line derivedfrom newborn mouse calvaria", J. CELL BIOL., vol. 96, 1983, pages 191 - 198, XP002000687, DOI: 10.1083/jcb.96.1.191

DOI:   http://dx.doi.org/10.1083/jcb.96.1.191
   SMITH EREDMAN RLOGG CCOETZEE GKASAHARA NFRENKEL B.: "Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle", J. BIOL. CHEM., vol. 275, 2000, pages 19992 - 20001
   LASIC, TRENDS BIOTECHNOL., vol. 16, no. 7, 1998, pages 1035 - 1038,1570-1580
   TAKAKURA, NIPPON RINSHO, vol. 56, no. 3, 1998, pages 691 - 95
   CHANDRAN ET AL., INDIAN J. EXP. BIOL., vol. 35, no. 8, 1997, pages 801 - 09
   MARGALIT, CRIT. REV. THER. DRUG CARRIER SYST., vol. 12, no. 2-3, 1995, pages 233 - 61
   QUINTANAR-GUERRERO ET AL., DRUG DEV. IND. PHARM., vol. 24, no. 12, 1998, pages 1113 - 28
   COUVREUR ET AL., CRIT. REV. THER. DRUG CARRIER SYST., vol. 5, no. 1, 1988, pages 1 - 20
   MUHLEN ET AL., EUR. J. PHARM. BIOPHARM., vol. 45, no. 2, 1998, pages 149 - 55
   ZAMBAUX ET AL., J. CONTROLLED RELEASE, vol. 50, no. 1-3, 1998, pages 31 - 40
   COMIER, CURR. OPIN. IN RHEU., vol. 7, 1995, pages 243
   GUINNESS-HEY, METAB. BONE DIS. RELAT. RES., vol. 5, 1984, pages 177 - 181
   BONE AND MINERAL, vol. 15, 1991, pages 175 - 192
   FROST, H.M.JEE, W.S.S.: "On the rat model of human osteopenias andosteoporosis", BONE AND MINERAL, vol. 18, 1992, pages 227 - 236, XP023072088, DOI: 10.1016/0169-6009(92)90809-R

DOI:   http://dx.doi.org/10.1016/0169-6009(92)90809-R
   JEE, W.S.S.YAO, W.: "Overview: animal models of osteopenia and osteoporosis", J. MUSCULOSKEL. NEURON. INTERACT., vol. 1, 2001, pages 193 - 207, XP055573206
   SUDO H ET AL.: "In vitro differentiation and calcification in a new clonal osteogenic cell line derivedfrom newborn mouse calvaria", J. CELL BIOL., vol. 96, pages 191 - 198, XP002000687, DOI: 10.1083/jcb.96.1.191

DOI:   http://dx.doi.org/10.1083/jcb.96.1.191
   SMITH EREDMAN RLOGG CCOETZEE GKASAHARA NFRENKEL B: "Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle", J BIOL CHEM, vol. 275, 2000, pages 19992 - 20001
   SUDO HKODAMA H-AAMAGAI YYAMAMOTO SKASAI S: "In vitro differentiation and calcification in a new clonal osteogenic cell line derivedfrom newborn mouse calvaria", J CELL BIOL, vol. 96, 1983, pages 191 - 198, XP002000687, DOI: 10.1083/jcb.96.1.191

DOI:   http://dx.doi.org/10.1083/jcb.96.1.191
   BYRNE, F. R. ET AL., GUT, vol. 54, 2005, pages 78 - 86
OppositionWO2005014650
 WO2005003158
 WO0032773
 EP1636270
   WARMINGTON ET AL.: "SCIEROSTIN ANTAGONISM IN ADULT RODENTS, VIA MONOCLONAL ANTIBODY MEDIATED BLOCKADE, INCREASES BONE MINERAL DENSITY AND IMPLICATES SCLEROSTIN AS A KEY REGULATOR OF BONE MASS DURING ADULTHOOD", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 19, ABSTRACT 1217, 5 October 2004 (2004-10-05), US , pages S56 - S57, XP009072609, ISSN: 0884-0431, DOI: 10.1359/JBMR.0301211

DOI:   http://dx.doi.org/10.1359/JBMR.0301211
   BEZOOIJEN VAN R L, ET AL: "Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 199, no. 6, 15 March 2004 (2004-03-15), US , pages 805 - 814, XP002391779, ISSN: 0022-1007, DOI: 10.1084/jem.20031454

DOI:   http://dx.doi.org/10.1084/jem.20031454
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.